PhRMA Statement on White House Cancer Moonshot Event

WASHINGTON, D.C. (February 2, 2022) — The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement following President Biden’s remarks to reignite the Cancer Moonshot:

“Cancer’s personal and societal toll is devastating, and we share President Biden’s strong commitment to eradicating this disease. New cancer medicines discovered and developed by America’s biopharmaceutical companies are helping patients lead longer, more productive lives. In the last three decades, the cancer death rate dropped by more than 30 percent, and with roughly 1,300 therapies in the research pipeline, patients with cancer have a lot of reason for hope.

“The science has never been more promising, but to have a successful moonshot, we cannot compromise the engine of innovation that is taking us there. That’s why we continue to urge lawmakers to reject any plan that would impose government price setting on innovative medicines. Instead, let’s work together to advance solutions that will lower the cost of medicines for patients while fueling the innovation that continues to make incredible progress against cancer and other devastating diseases.”

For more information on the importance of protecting innovation within R&D, please see here.

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1 trillion in the search for new treatments and cures, including $91.1 billion in 2020 alone.

Connect with PhRMA

For information on how innovative medicines save lives, please visit: